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Abstract
Background: Rheumatoid arthritis (RA) is a long term condition that requires early treatment to control symptoms
and improve long-term outcomes. Lack of response to RA treatments is not only a waste of healthcare resources,
but also causes disability and distress to patients. Identifying biomarkers predictive of treatment response offers an
opportunity to improve clinical decisions about which treatment to recommend in patients and could ultimately
lead to better patient outcomes. The aim of this study was to explore the understanding of and factors affecting
Rheumatoid Arthritis (RA) patients’ decisions around predictive treatment testing.
Methods: A qualitative study was conducted with a purposive sample of 16 patients with RA from three major UK
cities. Four focus groups explored patient perceptions of the use of biomarker tests to predict response to treatments.
Interviews were audio-recorded, transcribed verbatim and analysed using thematic analysis by three researchers.
Results: Data were organised within three interlinking themes: [1] Perceptions of predictive tests and patient
preference of tests; [2] Utility of the test to manage expectations; [3] The influence of the disease duration on take up
of predictive testing. During consultations for predictive testing, patients felt they would need, first, careful explanations
detailing the consequences of untreated RA and delayed treatment response and, second, support to balance the risks
of tests, which might be invasive and/or only moderately accurate, with the potential benefits of better management
of symptoms.
Conclusions: This study provides important insights into predictive testing. Besides supporting clinical decision
making, the development of predictive testing in RA is largely supported by patients. Developing strategies which
communicate risk information about predictive testing effectively while reducing the psychological burden associated
with this information will be essential to maximise uptake.
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Background
Rheumatoid arthritis (RA) is a long term condition that
requires early treatment to control symptoms and im-
prove long-term outcomes [1]. Lack of response to
RA treatments is not only a waste of healthcare re-
sources [2], but also causes disability and distress to
patients. Treating RA is not a uniform approach and
significant non-response rates are reported for all the
commonly used medications including both non-
biologic and biologic disease modifying anti-rheumatic
drugs (DMARDs). It would be ideal to target available
treatments to individual patients based on their likeli-
hood of response to ensure that remission is achieved
in the fastest time. However, currently, effective treat-
ments can only be identified through trial and error,
often over prolonged periods. If it was possible to
predict with a reasonably high degree of certainty
that a treatment for RA is likely to be effective for an
individual patient, treatment response rates and time
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to remission may improve whilst costs due to wastage
of healthcare resources would be reduced.
Identifying biomarkers predictive of treatment re-
sponse offers an opportunity to improve clinical deci-
sions about which treatment to recommend in patients
and could ultimately lead to better patient outcomes [3].
Currently, methotrexate is typically prescribed as the
first choice DMARD to treat RA either as mono or com-
bined therapy but by two years, up to 45 % of patients
have moved to other therapies [4]; patients who fail to
respond to methotrexate can be prescribed another
DMARD, or a biologic drug, which modulates the im-
mune system and/or inflammatory pathways to alleviate
disease. However, up to 25 % of patients prescribed anti-
TNF and 40 % of patients given rituximab biologic ther-
apies show inadequate response by 6 months of treat-
ment [5, 6]. This is important because early, effective
intervention has been consistently shown to improve
long-term outcomes including disability and joint dam-
age. Therefore, there appears to be an unmet clinical
need to identify biomarkers that would allow clinicians
to select the treatment most likely to work for a patient,
before the treatment is administered, based on some
form of test; such a test may incorporate a number of
factors including demographic, and clinical measures
but may also use results from blood and/or tissue
sample tests. Identified factors are called predictive
biomarkers or theranostic biomarkers and are used
extensively in the cancer therapeutic field; for ex-
ample, expression of the estrogen receptor (ER) gene
predicts response to tamoxifen in patients with breast
cancer and such tests are used routinely to help se-
lect the most appropriate treatments for individual
patients [6]. In RA, no predictive tests are yet avail-
able but numerous research studies are underway
with the aim of identifying such biomarkers. The cost
of testing will vary according to the particular marker
identified but a recent study investigating the costs of
a blood based testing of drug levels to anti-TNF biologic
drugs estimated that it would cost £152.52/patient (range:
£147.68 to 159.24) [7]. However, before making recom-
mendations about introducing such theranostic testing
into the clinical setting, it is important to understand the
patient perspectives and preferences. This requires an
understanding of the range of effects that predictive
testing can have on RA patients. This study explored
the factors that might influence a patients’ decision to
agree to different tests.
Methods
A qualitative study was undertaken in which explorative
focus groups were conducted with RA patients from
Manchester, Birmingham and London, UK. Patients with
a diagnosis of RA and who were taking synthetic or
biologic DMARDs were recruited from the National
Rheumatoid Arthritis Society (www.nras.org.uk) and
through established patient user groups. Patients were
selected purposively to ensure a mixture of age, gender
and employment status. Invitation letters were sent to
suitable patients and those that agreed to take part in
the study were invited to a focus group interview. All
study participants provided their written consent.
Four focus groups were conducted with 16 patients at
three sites (The University of Manchester, the University
of Birmingham and the Centre for Experimental Medi-
cine & Rheumatology, London) in areas designated for
research. By working with the MATURA patient advis-
ory group (www.matura.whri.qmul.ac.uk), we developed
a topic guide for the interviews where two scenarios were
presented to patients: [1] use of synovial biopsy-based
testing and [2] use of blood tests to inform treatment se-
lection each with different levels of accuracy for predicting
future response. Patients were briefly reminded of the
background and aim of the study, were asked to reflect on
the scenarios and their views on decision making around
the tests explored. The interviewer used open questions to
encourage emergence of participants’ ideas.
All focus groups interviews were audio-recorded, tran-
scribed verbatim, anonymised and analysed using the-
matic analysis where saturation of themes were
determined [8]. The data gathered from the focus groups
were analysed by thematic analysis [9] in which initial
analytical summaries of the focus group interviews were
coded line by line; the coding framework was discussed
by three researchers and coding categories that lacked
concordance were absorbed back into the coding
framework. The initial codes were then grouped into
the most frequently occurring categories. The core
themes extracted and presented here focus on percep-
tions of predictive testing and patients’ views about the
understanding of these tests. Data collection and ana-
lysis occurred in parallel to allow for an assessment of
when thematic saturation had been achieved, i.e., the
point at which no new ideas emerged [8].
Results
In the four focus groups, (Table 1). The majority (n = 13)
of the participants were female. The age range of the
participants was 26–80 years old and disease duration
Table 1 Details of RA patients who took part in the interviews
Gender 13 female, 3 male
Age range and mean Range: 26–80 mean: 42
Employment status employed full time: 5, self-employed; 1, retired;
4 retired due to RA;6
Range of year of disease Range: 3–34 years
Interview Place Birmingham; 3, London; 5, Manchester; 8 participants
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was 3–34 years. Eight participants had retired, four were
semi-retired and four were in full-time employment.
The data are organised into three superordinate
themes: [1] Perceptions of predictive tests and patient
preference of tests; [2] Utility of the test to manage ex-
pectations; [3] The influence of the disease duration on
take up of predictive testing. Each theme is illustrated
with quotations extracted from the transcripts.
[1] Perceptions of predictive tests and patient preference
of tests
Participants’ perceptions towards predictive testing were
largely positive as participants viewed predictive testing
as potentially helpful to impart new information about
which treatment could best control their symptoms, im-
prove quality of life and reduce disability. Participants
were strongly motivated to reduce delays in finding an
effective treatment, reduce the likelihood of side effects
and achieve remission more quickly.
Participants expressed concerns about the pain related
to a synovial biopsy procedure but balanced this anxiety
with the benefit of assumed increased predictive accur-
acy. Hence they were prepared to undergo a biopsy if
this increased the accuracy of the test. Indeed the bene-
fits of the possibility of better management of their con-
dition were so valued that this trade-off was acceptable
even when the probability of finding an accurate treat-
ment was low (Table 2 Quotations 1–9).
Table 2 Patient Quotes
Themes
Perceptions of predictive tests and patient
preference of tests
Quote 1: I wouldn’t hesitate if there was any option to do anything at all that would be likely to make your
life better. [female, left work due to RA]
Quote 2: I would have loved to have continued my job, and had I had this kind of test done I would
probably still be in my job. [female, retired]
Quote 3. Because there’s quite a lot of waiting around, even after you’re prescribed a specific drug, and then
even more because I’m just going through the process of swapping them again …So anything that reduces
that amount of time that you have to wait and knowing that when you are on the drug it’s more likely to
work rather than trial and error and just seeing whether it does work would definitely be something that I
would consent to. [female, full-time employment]
Quote 4: My answer to that would be yes the biopsy would be more painful to go through but, if that was
the best your test had produced in the biopsy…say 50 % or 60 % then I would go with that in the hope that
you would refine and improve the quality of life. [female, retired]
Quote 5: I think the biopsy would give you a better indication, rather than a blood test. [male retired]
Quote 6: I would still take the drug if the test indicated that it only had a 20 % chance of effectiveness.
[male, full-time employment]
Quote 7: “it will mean that you don’t have to go through years and years of trying different drugs, I think
then I wouldn't even question the biopsy test”. [female, retired]
Quote 8: “I think, for me, the big thing would be accuracy and how accurate it is; if the biopsy tells you more
then that’s what I should go for. [female, full-employment]
Quote 9: Yeah, similar. I mean, I guess, it depends in part, how accurate you think it could be… Like you say,
it’s not such a major procedure [referring to biopsy] or whatever, but would be worth having a go at it”.
[female, full-employment]
Utility of the test to manage expectations Quote 10: I think it’s probably more of a personality sort of thing. I would imagine two people hear the same
information and they react differently [male retired]
Quote 11: I’m a research scientist, so for me, I’m just nosy. The more I know about what’s going on, the more
I can manage my expectations. But I guess that’s not true for most patients. So it’s trying to think of what
other people would say…[female, full-employment]
Quote 12: I can see if you’ve pinned your hopes on something and it comes back ten per cent, this isn’t
going to work for you, then yes, you might want to speak to someone. Yeah, because you’re sort of…so you
almost go through a grief process, don’t you? [female, full-employment]
The stages of illness on decision making
for predictive testing
Quote 13: I think it goes without saying. I think a test such as that, if you’re new to it you’re not aware of
the journey that you’re going to undertake with rheumatoid. [male, retired]
Quote 14: “it’s barely an operation, and it’s going to help my clinicians have a better understanding of my
profile, absolutely, 100 %. But it’s a question of understanding the potential journey. If you don’t understand
the impact of life then you think, well, why is it necessary?”. [female left work due to RA]
Quote 15: “I think anything…as a newly diagnosed patient, or going through that diagnosis process, any
sort of conversation about medications is helpful and if tests are the way forward to predict and control
disease then that should be explained” [female full-employment]
Quote 16: “Right at the beginning you don’t know what it’s going to be like, what the side effects of the
medication are going to be like, so as long as that is all explained to the patients this is what happens with
rheumatoid arthritis then the new ones will have a better idea”. [female, left work due to RA]
Quote 17: “The group of us here are clearly enlightened and we understand what’s involved. Some are
educated, some are partially educated and some are highly educated, but, from my experience, the majority
have little understanding of what their condition is”. [male, retired]
Quote 18: “I mean, it might be probably better if you get new patients to have them all in one clinic where
somebody could explain what the condition is that they have once they’ve had their blood tests, and then
seen individually by a consultant following that group thing where they’ve been told what they’ve got, what
treatments there are, what further tests they need” [female, left work due to RA]
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[2] Utility of the test to manage expectations
Participants expressed the view that there may be inter-
individual variation in the interpretation of test results.
It was argued that people may react differently towards
the results of tests even though they receive the same
test result and those who place a high expectation on
the test result may be more disappointed and need more
reassurance if the test result showed a low probability of
efficacy of a particular drug. Some participants thought
that knowing that the test might have a low accuracy
may help them to manage their expectations. However,
if an accurate test produced a result indicating a low
likelihood of benefit for a particular treatment, that
could create a sense of loss about how and to what level
the symptoms might be controlled. Regardless, partici-
pants felt that they would need additional support to
understand the risk and cope with the emotional impact
of a test that predicted a low probability of response
(Table 2 Quotations 10–12).
[3] The influence of the disease duration on take up of
predictive testing
Amongst participants, there was a view that the stage of
the disease course could influence a patient’s willingness
to engage in predictive testing. Participants were con-
cerned that the value of a predictive theranostic bio-
marker test may not be recognised by those with
recently diagnosed RA; by contrast, those with estab-
lished RA might value the predictive testing more in
determining their treatment plan since they would have
had experience of the fluctuant condition and the ex-
tent to which it impacts on life. It was thought that
those with limited RA experience would require more
convincing information and careful explanations about
the utility of predictive testing and how that would add
value in determining a timely treatment plan (Table 2
Quotations 13–18).
Discussion
This is the first study to explore the understanding of
and factors affecting RA patients’ decisions around tests
that predict likely treatment efficacy. Whilst such tests
are largely still hypothetical, there are a number of initia-
tives to identify accurate and reliable theranostic bio-
markers and it is reassuring to note, therefore, this study
evaluated patient perceptions towards the concept of
predictive testing, not the tests themselves, these per-
ceptions were very positively overall. Even though syn-
ovial biopsy was viewed as being a painful and invasive
procedure, and some had concerns about tests with
only low-moderate accuracy, these were outweighed by
the potential benefits of accessing new information
that could reduce delays in finding an effective treat-
ment. One recommendation that emerged was the
need for information provision before predictive test-
ing, particularly about the consequences of uncon-
trolled disease activity so that the risks of the test
could be balanced with the current trial-and-error ap-
proach of therapy selection.
In keeping with previous studies investigating the risk
of developing inflammatory diseases [10], negative views
were expressed if the test failed to meet the patients’ ex-
pectations. Thus, some concerns were raised about the
effect of learning that a test predicted a low probability
that a treatment would be effective as this may cause
anxiety and be viewed as a negative. Moreover, this
could be particularly distressing for patients with newly
diagnosed disease. By contrast, a test result showing a
high probability of efficacy may improve adherence
levels. These findings highlight the need for careful sup-
port to minimise distress for patients and map onto
similar issues that have been explored in studies investi-
gating the views of genetic testing in people at risk of in-
flammatory disease [11–14]. In those studies, a staged
approach has been recommended [10, 15] incorporating
provision of information prior to testing, providing help
to interpret the results [13, 16] and finally offering psy-
chological support [17]. In general, patient understand-
ing of predictive testing is likely to be variable [15] and
we recommend that clinics considering offering patients
predictive testing pay particular attention to the impact
that the negative result might have on the individual pa-
tient. Patients at different stages of their disease might
react differently to predicative testing. For example, pa-
tients with established disease duration might be more
willing to try tests since they would have had more ex-
perience with treatments that might not have worked
effectively. Future work should be conducted in newly-
diagnosed patients, who were not well-represented in
the current study, to determine whether the factors in-
fluencing on the decision to undergo predictive testing
are the same or not.
This study has a number of limitations. Firstly, our ac-
cess to patients was via patient user groups and charity
organisations. These patients might be very proactive in
their views and be motivated to support research and in-
novative approaches. The findings presented may not,
therefore, fully reflect the range of views related to pre-
dictive testing in the general clinic setting. Given the
finding that stage of illness may be a factor in acceptabil-
ity of predictive testing, exploring this further in those
newly diagnosed would be an important next step. A
second limitation was that the majority of patients were
female Caucasian. Previous work in rheumatology has
been criticised for underrepresenting the male perspec-
tive [18] and those of Black and minority ethnic groups.
Whilst efforts were made to engage these more difficult
to reach groups, the focus groups are unlikely to be fully
Kumar et al. BMC Musculoskeletal Disorders  (2016) 17:460 Page 4 of 6
representative. A full understanding of the cultural bar-
riers (including ethnicity, gender and religion) related to
predictive testing was not captured and is an area for
further research as the support required in these popula-
tions may differ. Despite these limitations our study also
has a number of strengths: first, patients were sampled
from three different centres across the UK; second, it is
the first that has attempted to explore the views of pa-
tients about predictive testing for RA treatments; third,
we have captured recommendations made by patients
that can be implemented to alleviate patient concerns if/
when predictive testing reaches the clinical setting and
finally, we have demonstrated the importance of individ-
ual circumstances and the clinical encounter in the ap-
praisal of predictive testing for treatment response in
RA clinics.
Conclusions
Predictive testing to better inform treatment selection
decisions is welcomed by RA patients, but support is
needed during the decision making process to help man-
age the impact of a result suggesting a low probability of
treatment efficacy, particularly for patients early in the
illness trajectory. Developing strategies which healthcare
professionals can use to communicate risk information
effectively while reducing the psychological burden asso-
ciated with this information is essential.
Abbreviations
DMARDs: Disease modifying anti-rheumatic drugs; RA: Rheumatoid arthritis
Acknowledgments
We would like to thank Rebecca Harrop for facilitating the interviews and
helping with data analysis. We would also like to thank Dr Lis Cordingley for
helping with data analysis. We are very grateful to the patient user group
within the MATURA cohort who helped shape the interview guide. We
would like to thank Deborah Maskell for organising the interviews.
MAximising Therapeutic Utility for RA (MATURA) Consortium members listed
on (www.matura.whri.qmul.ac.uk)
Funding
This study was funded by an MRC/Arthritis Research UK award: Maximising
Therapeutic Utility in RA (MATURA), grant ref: MR-K015346. This report includes
independent research supported by the NIHR Manchester Musculoskeletal
Biomedical Research Unit. The views expressed in the publication are those
of the authors and not necessarily those of the NHS, the National Institute
of Health Research or the Department of Health.
Availability of data and materials
The dataset (s) supporting the conclusions of this article are included within
the article.
Authors’ contributions
KK and AB developed the protocol for the study. KK conducted the study.
KK, analysed the data; SP verified the development of overarching themes.
All authors contributed to the drafted manuscript. KK is the guarantor of this
paper. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participation
Ethical approval was obtained from the Ethics Committee of the University of
Manchester, UK (Reference number 15176). All patients provided written consent.
Author details
1School of Health Sciences, University of Manchester, Manchester M13 9PL,
UK. 2Arthritis Research UK Centre for Genetics and Genomics Centre for
Musculoskeletal Research, Institution of Inflammation and Repair, University
of Manchester, Manchester M13 9PL, UK. 3Manchester Centre for Health
Psychology, School of Health Sciences, Manchester M13 9PL, UK. 4NIHR
Manchester Musculoskeletal BRU, Central Manchester Foundation Trust,
Manchester Academic Health Sciences Centre, Manchester, UK.
Received: 8 July 2016 Accepted: 1 November 2016
References
1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The
prevalence of rheumatoid arthritis in the United Kingdom: new estimates
for a new century. Rheumatology (Oxford). 2002;41(7):793–800.
2. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et
al. EULAR recommendations for the management of rheumatoid arthritis
with synthetic and biological disease-modifying antirheumatic drugs: 2013
update. Ann Rheum Dis. 2014;73(3):492–509.
3. Gonzalez-Alvaro I, Ortiz AM, Seoane IV, Garcia-Vicuna R, Martinez C, Gomariz
RP. Biomarkers predicting a need for intensive treatment in patients with
early arthritis. Curr Pharm Des. 2015;21(2):170–81.
4. Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte
LB, et al. Drug survival, efficacy and toxicity of monotherapy with a fully
human anti-tumour necrosis factor-alpha antibody compared with
methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford).
2002;41(4):430–9.
5. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to
anti-TNF-alpha therapy among patients with rheumatoid arthritis: results
from the British Society for Rheumatology Biologics Register. Rheumatology
(Oxford). 2006;45(12):1558–65.
6. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, et al.
American society of clinical oncology clinical practice guideline update on
the use of pharmacologic interventions including tamoxifen, raloxifene, and
aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;
27(19):3235–58.
7. Jani M, Gavan S, Chinoy H, Dixon WG, Harrison B, Moran A et al. A
microcosting study of immunogenicity and tumour necrosis factor alpha
inhibitor drug level tests for therapeutic drug monitoring in clinical practice.
Rheumatology (Oxford). 2016. pp. 113-9. doi:10.1093/rheumatology/kew292.
8. Dixon-Woods M, Agarwal S, Jones D, Young B, Sutton A. Synthesising
qualitative and quantitative evidence: a review of possible methods. J
Health Serv Res Policy. 2005;10(1):45–53.
9. Greenhalgh T, Campbell-Richards D, Vijayaraghavan S, Collard A, Malik F,
Griffin M, et al. New models of self-management education for minority
ethnic groups: pilot randomized trial of a story-sharing intervention. J
Health Serv Res Policy. 2011;16(1):28–36.
10. Lewis JR, Konda V, Rubin DT. Genetic testing for inflammatory bowel
disease: focus group analysis of patients and family members. Genet Test
Mol Biomarkers. 2009;13(4):495–503.
11. Adriaanse MC, Snoek FJ. The psychological impact of screening for type 2
diabetes. Diabetes Metab Res Rev. 2006;22(1):20–5.
12. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of
perceived risks, psychological and behavioral impacts of genetic testing.
Genet Med. 2008;10(1):19–32.
13. Markowitz SM, Park ER, Delahanty LM, O’Brien KE, Grant RW. Perceived
impact of diabetes genetic risk testing among patients at high phenotypic
risk for type 2 diabetes. Diabetes Care. 2011;34(3):568–73.
14. Kasparian NA, Meiser B, Butow PN, Job RF, Mann GJ. Better the devil you
know? High-risk individuals’ anticipated psychological responses to genetic
testing for melanoma susceptibility. J Genet Couns. 2006;15(6):433–47.
15. Honey S, Hill K, Murray J, Craigs C, House A. Patients’ responses to the
communication of vascular risk in primary care: a qualitative study. Prim
Health Care Res Dev. 2015;16(1):61–70.
16. Eborall H, Davies R, Kinmonth AL, Griffin S, Lawton J. Patients’ experiences
of screening for type 2 diabetes: prospective qualitative study embedded in
Kumar et al. BMC Musculoskeletal Disorders  (2016) 17:460 Page 5 of 6
the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007;
335(7618):490.
17. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S.
Psychological impact of screening for type 2 diabetes: controlled trial and
comparative study embedded in the ADDITION (Cambridge) randomised
controlled trial. BMJ. 2007;335(7618):486.
18. Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. Delays in help
seeking at the onset of the symptoms of rheumatoid arthritis: a systematic
synthesis of qualitative literature. Ann Rheum Dis. 2012;71(4):493–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kumar et al. BMC Musculoskeletal Disorders  (2016) 17:460 Page 6 of 6
